Year |
Citation |
Score |
2017 |
Mehla K, Tremayne J, Grunkemeyer JA, O'Connell KA, Steele MM, Caffrey TC, Zhu X, Yu F, Singh PK, Schultes BC, Madiyalakan R, Nicodemus CF, Hollingsworth MA. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunology, Immunotherapy : Cii. PMID 29204701 DOI: 10.1007/S00262-017-2095-7 |
0.515 |
|
2014 |
Liu X, Yi C, Wen Y, Radhakrishnan P, Tremayne JR, Dao T, Johnson KR, Hollingsworth MA. Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. Cancer Research. 74: 1609-20. PMID 24371222 DOI: 10.1158/0008-5472.Can-13-2444 |
0.575 |
|
2013 |
Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle R, Harris AL, Friedman LS, Belvin M, Middleton MR, Blackwood EM, et al. P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. Journal of the National Cancer Institute. 105: 606-7. PMID 23535073 DOI: 10.1093/Jnci/Djt054 |
0.349 |
|
2012 |
Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T, Tremayne J, Ross LB, Pei Z, Friedman LS, Blackwood EM, Belvin M. mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer Letters. 326: 168-75. PMID 22902509 DOI: 10.1016/j.canlet.2012.08.011 |
0.323 |
|
2011 |
Eggers JP, Grandgenett PM, Collisson EC, Lewallen ME, Tremayne J, Singh PK, Swanson BJ, Andersen JM, Caffrey TC, High RR, Ouellette M, Hollingsworth MA. Cyclin-dependent kinase 5 is amplified and overexpressed in pancreatic cancer and activated by mutant K-Ras. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6140-50. PMID 21825040 DOI: 10.1158/1078-0432.Ccr-10-2288 |
0.345 |
|
2007 |
Ashour AE, Turnquist HR, Burns N, Wang X, Lin X, Tremayne J, Hollingsworth MA, Blonder JM, Rosenthal GJ, Talmadge JE, Solheim JC. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma. Cancer Biotherapy & Radiopharmaceuticals. 22: 235-8. PMID 17600470 DOI: 10.1089/Cbr.2007.336 |
0.572 |
|
Show low-probability matches. |